Home » Posts tagged with » Adcetris
Takeda gets extended EC approval for ADCETRIS in sALCL

Takeda gets extended EC approval for ADCETRIS in sALCL

Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) in adult patients. The approval from the European Commission (EC) is for the combination of ADCETRIS with CHP (cyclophosphamide, doxorubicin, prednisone. It comes in the wake of a […]

Takeda bags ADCETRIS EC approval for CD30+ Stage IV Hodgkin lymphoma

ADCETRIS EC approval : The European Commission (EC) has expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to cover treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adult patients. ADCETRIS is an antibody-drug conjugate (ADC) that targets CD30, which is a defining marker of […]

Continue reading …
Seattle Genetics’ Adcetris gets FDA approval for peripheral T-cell lymphoma

Adcetris FDA approval : Seattle Genetics has secured new approval from the US Food and Drug Administration (FDA) for its monoclonal antibody Adcetris (brentuximab vedotin), which is in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) for the treatment of certain types of peripheral T-cell lymphoma (PTCL). Adcetris FDA approval for PTCL in combination with CHP […]

Continue reading …